VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · IEX Real-Time Price · USD
0.630
+0.011 (1.78%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally.
The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
VolitionRx Limited is based in Henderson, Nevada.
VolitionRx Limited
| Country | United States |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Cameron Reynolds MBA |
Contact Details
Address: 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States | |
| Phone | 1 (646) 650-1351 |
| Website | volition.com |
Stock Details
| Ticker Symbol | VNRX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000093314 |
| CUSIP Number | 928661107 |
| ISIN Number | US9286611077 |
| Employer ID | 91-1949078 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Salvatore Thomas Butera DVM | Chief Executive Officer of Volition Veterinary Diagnostics Development LLC |
| Cameron Reynolds MBA | Founder, Chief Executive Officer, President and Director |
| Dr. Martin Charles Faulkes Ph.D. | Executive Chairman |
| Dr. Gaetan Michel Ph.D. | Chief Operating Officer |
| Terig Hughes | Chief Financial Officer and Treasurer |
| Dr. Jacob Vincent Micallef MBA, Ph.D. | Chief Scientific Officer |
| Nicholas Plummer | Group General Counsel |
| Louise Batchelor Day | Group Chief Marketing and Communications Officer |
| Thomas Bygott | Sales and Marketing Director |
| Gael Forterre M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| Jun 25, 2024 | EFFECT | Notice of Effectiveness |
| Jun 25, 2024 | 424B3 | Prospectus |
| Jun 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 13, 2024 | DEF 14A | Other definitive proxy statements |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 26, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 26, 2024 | 8-K | Current Report |
| Mar 26, 2024 | D | Notice of Exempt Offering of Securities |